Immunic Inc (IMUX) Reports Year-End 2023 Financial Results [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
Clinical Developments : Positive interim analysis from Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis. Patent Portfolio Expansion : New patents granted, extending exclusivity protection into 2041 in the U.S. Research and Development Expenses : Increased to $83.2 million in 2023 from $71.3 million in 2022. Net Loss : Reported a net loss of $93.6 million in 2023, an improvement from a net loss of $120.4 million in 2022. Cash and Cash Equivalents : Decreased to $46.7 million at the end of 2023 from $106.7 million at the end of 2022. Warning! GuruFocus has detected 2 Warning Signs with IMUX. On February 22, 2024, Immunic Inc ( NASDAQ:IMUX ) released its 8-K filing , announcing the financial results for the fourth quarter and year ended December 31, 2023, along with a corporate update. The clinical-stage biopharmaceutical company, which focuses on developing oral immunology therapies for chronic inflammatory and autoimmune diseases, reported a
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal [Yahoo! Finance]Yahoo! Finance
- Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update [Yahoo! Finance]Yahoo! Finance
- Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdatePR Newswire
- Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationPR Newswire
IMUX
Earnings
- 11/14/23 - Beat
IMUX
Sec Filings
- 5/1/24 - Form EFFECT
- 4/30/24 - Form 424B3
- 4/23/24 - Form DEF
- IMUX's page on the SEC website